Trial Profile
Bone mineral density response to raloxifene monotherapy or in combination with alfacalcidol in postmenopausal Japanese women with osteoporosis or osteopenia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2012
Price :
$35
*
At a glance
- Drugs Raloxifene (Primary) ; Alfacalcidol
- Indications Bone resorption; Metabolic bone diseases; Postmenopausal osteoporosis
- Focus Therapeutic Use
- 20 Sep 2011 2 year results presented at the 33rd Annual Meeting of the American Society for Bone and Mineral Research.
- 05 Nov 2010 New trial record.